3 days popular7 days popular1 month popular3 months popular

‘Trained immunity’ mediates BCG therapy of bladder cancer

Bacillus Calmette-Guerin (BCG) is a vaccine widely used in low and middle-income countries to protect against childhood tuberculosis. Besides its specific anti-tuberculosis effects, BCG can also function as a general immune-booster, and in this capacity is used in the treatment of certain bladder cancers. A study published in PLOS Pathogens now reports that autophagy (the removal and degradation of unnecessary or dysfunctional components within cells) plays a central role in mediating the non-specific immune effects of BCG.

[Autophagy]
This image shows autophagy affected by SNP in ATG2B.
Credit: Joosten et al. CC-BY 4.0


Source

Authors and Affiliations:

Kathrin Buffen, ,

Marije Oosting, Medical Center, The Netherlands

Jessica Quintin, Radboud , The Netherlands

Aylwin Ng, The Broad Institute of Massachusetts Institute of Technology and Harvard University, USA;

Massachusetts , Harvard Medical School, USA

Johanneke Kleinnijenhuis, Radboud University Medical Center, The Netherlands

Vinod Kumar, , University Medical Center Groningen, The Netherlands

Esther van de Vosse, Leiden University Medical Center, The Netherlands

Cisca Wijmenga, University of Groningen, University Medical Center Groningen, The Netherlands

Reinout van Crevel, Radboud University Medical Center, The Netherlands

Egbert Oosterwijk, Radboud University Medical Center, The Netherlands

Anne J. Grotenhuis, Radboud University Medical Center, The Netherlands

Sita H. Vermeulen, Radboud University Medical Center, The Netherlands

Lambertus A. Kiemeney, Radboud University Medical Center, The Netherlands

Frank L. van de Veerdonk, Radboud University Medical Center, The Netherlands

Georgios Chamilos, University of Crete, Greece

Ramnik J. Xavier, The Broad Institute of Massachusetts Institute of Technology and Harvard University, USA;

Massachusetts General Hospital, Harvard Medical School, USA

Jos W. M. van der Meer, Radboud University Medical Center, The Netherlands

Mihai G. Netea, Radboud University Medical Center, The Netherlands

Leo A. B. Joosten, Radboud University Medical Center, The Netherlands

Funding:

KB is supported by a grant of the Dutch Arthritis Foundation (NR 10-1-303). MGN is supported by a Vici grant of the Netherlands Organization for Scientific Research. CW is supported by an grant from the European Research Council under the European Union’s Seventh Framework Program (FP/2007–2013)/ERC Grant Agreement no. 2012- 322698. RvC is supported by a Vidi grant of the Netherlands Organization for Scientific Research (017.106.310). AG is supported by a research investment grant of the Radboud University Medical Centre (RUMC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

The authors have declared that no competing interests exist.

Citation:

Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J, et al. (2014) >Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer PLoS Pathog 10(10): e1004485. doi:10.1371/journal.ppat.1004485

PLOS